+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.

Age: 18Years +All GendersPhase 3
217 locations
B

Actively Recruiting

Researchers are conducting the BRAVO study, a multicenter observational research project focused on adults aged 18 and over living with HIVAIDS across Brazil. The study aims to gather detailed information about chronic non-communicable diseases NCDs, mental health, and quality of life in this population to help develop better health policies. It includes participants from various regions in Brazil and emphasizes the importance of understanding cardiometabolic health, mental health, and other risk factors among people living with HIVAIDS. The study collects a wide range of data including sociodemographic details, risk factors for main NCDs, physical examination results, and biological samples for biochemical and metabolic testing. It uses validated tools and some project-developed questionnaires to assess conditions such as depression, anxiety, substance use, and quality of life through the WHOQOL-BREF survey. Data are managed using REDCap software and cover clinical lab tests, physical measures, respiratory function, renal, hepatic, and bone health, as well as sexually transmitted infections and cancer risk assessments. Participants will provide informed consent and undergo a cross-sectional baseline assessment during 2025 and 2026. Researchers will measure the prevalence of chronic diseases, mental disorders, metabolic and behavioral risk factors, antiretroviral therapy adherence, and quality of life at baseline and one year later. The study plans subgroup analyses for specific populations and ensures confidentiality and ethical compliance. Participation involves data collection through questionnaires, exams, and sample collection, with a target of 743 participants to ensure reliable results.

Age: 18Years +All Genders
9 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of DYNAVISC in adults diagnosed with persistent or recurrent carpal tunnel syndrome after previous surgery. This randomized, evaluator-blinded clinical trial compares two methods of protecting the median nerve during revision surgery standard care surgery followed by applying DYNAVISC around the nerve, and standard care surgery followed by using a hypothenar fat pad flap to cover the nerve. The study is focused on reducing pain and improving nerve recovery after surgery. Participants will undergo revision surgery and be assigned to one of the two groups. In the group receiving DYNAVISC, a 1 ml dose will be applied over and around the median nerve at the repair site during surgery. All participants will begin gentle wrist and finger movements immediately after surgery and gradually increase activity, allowing strenuous movements starting six weeks post-surgery. Their hands will be evaluated at 1 week, 4 weeks, and 12 weeks following surgery. Throughout the study, participants will record their pain levels using a visual analog scale and assess hand function with the Quick DASH score. Neuropathic pain will be measured with the DN4 score, and nerve recovery will be assessed through electroneuromyography testing. Grip strength will also be measured with a dynamometer. All assessments will be conducted by personnel unaware of group assignments. The total study duration includes monitoring outcomes up to 12 weeks after surgery.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
4 locations